Combs D W, Reese K, Cornelius L A, Gunnet J W, Cryan E V, Granger K S, Jordan J J, Demarest K T
R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869-0602, USA.
J Med Chem. 1995 Dec 8;38(25):4880-4. doi: 10.1021/jm00025a004.
A novel series of nonsteroidal heterocycles was discovered which display cell-type selective, high-affinity (nanomolar) binding to the progesterone receptors from TE85 osteosarcoma cells but > 1 microM binding affinity to the progesterone receptors from T47D and ZR75 human breast carcinoma cells. Structure-activity relationships were developed for a set of these compounds, and a representative analog 1-(3,4-dichlorobenzoyl)-3-phenyl-1,4,5,6-tetrahydropyridazine++ + (1i, RWJ 25333) was chosen for further evaluation. RWJ 25333 stimulated the in vitro proliferation of human osteoblast-like cells but not human breast cells.
发现了一系列新型非甾体杂环化合物,它们对TE85骨肉瘤细胞的孕酮受体具有细胞类型选择性、高亲和力(纳摩尔级)结合,但对T47D和ZR75人乳腺癌细胞的孕酮受体结合亲和力>1微摩尔。针对一组此类化合物建立了构效关系,并选择了一种代表性类似物1-(3,4-二氯苯甲酰基)-3-苯基-1,4,5,6-四氢哒嗪(1i,RWJ 25333)进行进一步评估。RWJ 25333刺激人成骨样细胞的体外增殖,但不刺激人乳腺细胞。